Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
1
Introduction
2
Case 1
3
Case 2
4
Case 3
Pre-Assessment Survey and Cases
Please complete these pre-activity survey questions, including selection of an appropriate treatment for each of three cases.
Enter your information to get started
Your Name
*
First
Last
Your Email
*
Pre-Activity Survey
Which therapies have you prescribed for R/R CLL/SLL in the past 6 months? (Select all that apply)
*
Ibrutinib
Acalabrutinib
Zanubrutinib
Pirtobrutinib
Venetoclax-containing regimens
Lisocabtagene maraleucel
PI3K-based regimens
Clinical trial participation
Other
Other, please specify
*
What is your primary rationale for prescribing a non-covalent BTK inhibitor (if applicable)?
*
Prior BTK inhibitor intolerance
Prior BTK inhibitor resistance (e.g., C481S)
Efficacy in R/R setting, based on recent evidence
Favorable safety profile
Participation in clinical trial
Other
Other, please specify
*
Which adverse events associated with BTK inhibitors have been difficult to manage in your patients with CLL/SLL? (Select all that apply)
*
Atrial fibrillation
Hypertension
Bleeding
Neutropenia
Thrombocytopenia
Infections
Pneumonitis
Diarrhea
Dermatological toxicities, nail and hair changes
Arthralgias and myalgias
Headache
Fatigue
How important are the following factors in guiding your treatment selection for your patients with R/R CLL/SLL? (Select the 3 most important factors)
*
Del(17p)
TP53 mutation status
IGHV mutation status
Age/frailty
Concomitant medications and/or change to comorbidities
Prior intolerance to BTK inhibitors
Patient preference/goals
Patient adherence-related factors
Explore Case 1 — Ms. Blanchard
Case 1 - Patient Profile
Ms. Blanchard
58-year-old fit female
R/R CLL
Medical History
Post-menopausal, G3P2, no other significant medical history
Initially diagnosed with stage I indolent CLL with watch and wait approach
Del(17p) on FISH
IGHV-unmutated
Complex karyotype
54-years-old when initially received ibrutinib + rituximab for CLL but was intolerant due to arthralgias and discontinued after 6 months despite dose reduction, and progressed shortly after fixed duration venetoclax + anti-CD20 monoclonal antibody
Current symptoms:
Night sweats
Fatigue
ECOG PS: 0
Subjective symptoms:
Weakness and fatigue
Expresses the following preferences:
No preference for regimen
Case 1 - Treatment
What treatment option would you select for this patient?
*
A. Ibrutinib
B. Acalabrutinib
C. Zanubrutinib
D. Pirtobrutinib
E. Venetoclax-based regimens
F. Lisocabtagene maraleucel
G. PI3K-based regimens
H. Clinical trial participation
I. Other
What other treatment option would you select for this patient?
*
Explore Case 2 — Mr. Rosenstein
Case 2 - Patient Profile
70-year-old moderate fitness male
R/R CLL
Medical History
Hypertension (controlled on metoprolol)
Family history of prostate cancer
Initially diagnosed with stage I indolent CLL with watch and wait approach
Del(17p) on FISH
IGHV-unmutated
Complex karyotype
65-years-old when initially received BR for his CLL then relapsed 3 years later, received ibrutinib and had atrial fibrillation
Current symptoms:
Night sweats
Fatigue
ECOG PS: 1
Subjective symptoms:
Weakness and fatigue
Expresses the following preferences:
No preference for regimen
Retiring this year and interested in traveling
Case 2 - Treatment
you your Treatment
What treatment option would you select for this patient?
*
A. Ibrutinib
B. Acalabrutinib
C. Zanubrutinib
D. Pirtobrutinib
E. Venetoclax-based regimens
F. Lisocabtagene maraleucel
G. PI3K-based regimens
H. Clinical trial participation
I. Other
What other treatment option would you select for this patient?
*
Explore Case 3 — Mr. Campbell
Case 3 - Patient Profile
Mr. Campbell
81-year-old frail male
R/R CLL
Medical History
Hypertension (controlled on furosemide)
Type 2 diabetes (controlled on metformin)
Previously diagnosed enlarged benign prostate
Initially diagnosed with stage III aggressive CLL
IGHV-unmutated
del(17p) and del(11q) on FISH
Relapsed 6 months after first-line therapy with BR for his CLL then received acalabrutinib but relapsed 2 years later
Current symptoms:
Lymphadenopathy (2 cm nodes on axillae/groin)
Lymphocytosis (4,000/mcL)
Anemia (Hb: 10 g/dL, Hct: 37%, RBC: 4.1 cells/mcL)
Fever and rapid weight loss
ECOG PS: 3
Subjective symptoms
Fatigue
Nausea
Expresses the following preferences:
Concerned about future relapse
Would prefer not to travel to hospital
Case 3 - Treatment
What treatment option would you select for this patient?
*
A. Ibrutinib
B. Acalabrutinib
C. Zanubrutinib
D. Pirtobrutinib
E. Venetoclax-based regimens
F. Lisocabtagene maraleucel
G. PI3K-based regimens
H. Clinical trial participation
I. Other
What other treatment option would you select for this patient?
*
Submit All Treatment Choices
Scroll to Top
